Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Caio Dabbous Liz"'
Autor:
Joyce Maria L. Maia, Angelo Bezerra de Souza Fêde, Monique Celeste Tavares, Vladmir Cláudio Cordeiro de Lima, Celso Silva e Souza Filho, Andrea Paiva Gadelha Guimarães, Solange Moraes Sanches, Caio Dabbous Liz, Bruno Cezar Mendonça Uchôa Júnior, Paula Tavares Guimarães, Lucas Vian, Mauro Daniel Spina Donadio, Adriana Regina Gonçalves Ribeiro, Marcelle Goldner Cesca, Ronaldo Pereira Souza, Augusto Saito, Iara Karoline Freire Lustosa, Samara Theodoro Pacheco, Luciana Beatriz Mendes Gomes, Noam Pondé, Marcelo Corassa, Fabrício de Souza Castro, M.F. Simões, Daniella Yumi Tsuji Honda
Publikováno v:
Cancer Research. 81:PS6-25
Background: Breast cancer (BC) accounts for 30% of female cancer, is the most commonly diagnosed cancer worldwide and the second most common cause of cancer-related deaths among females. The majority (79%) of breast cancers express the estrogen recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df7f94703f115c488e53f12922720d2f
https://doi.org/10.1158/1538-7445.sabcs20-ps6-25
https://doi.org/10.1158/1538-7445.sabcs20-ps6-25
Autor:
Monique Celeste Tavares, Marcos Rezende Teixeira, João Pedreira Duprat, Daniel Garcia, Joao Lima, Thiago Bueno Oliveira, Marcelo Cavicchioli, Caio Dabbous Liz, Eduardo Lima, José Augusto Rinck, Luciana Beatriz Mendes Gomes Siqueira, Milton Jose De Barros E. Silva
Publikováno v:
Journal of Clinical Oncology. 39:e21533-e21533
e21533 Background: Combination therapy with anti-PD1 and low-dose ipilimumab has shown reduced rate of immune-related adverse effects compared with standard dose used in the Checkmates studies 067 and 204. However, the discussion whether low-dose ipi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86e68470420f62bae938099a9a006149
https://doi.org/10.1200/jco.2021.39.15_suppl.e21533
https://doi.org/10.1200/jco.2021.39.15_suppl.e21533
Autor:
José Augusto Rinck, Daniel Garcia, Matheus de Melo Lôbo, Marcelo Cavicchioli, Marcos Rezende Teixeira, Eduardo Bertolli, João Pedreira Duprat, Kenneth J. Gollob, Clovis Antonio Lopes Pinto, Caio Dabbous Liz, André Sapata Molina, Joao Lima, Eduardo Lima, Amanda B. Figueiredo, Monique Celeste Tavares, Milton Jose De Barros E. Silva
Publikováno v:
Journal of Clinical Oncology. 39:e21569-e21569
e21569 Background: Neoadjuvant immunotherapy with nivolumab 3mg/kg and ipilimumab 1mg/kg for two cycles(N3+I1) or anti-PD1 for 3-8 weeks for clinical stage III melanoma have shown rates of pCR/near-pCR about 60% or 30%, respectively. The prognosis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc0285f067003e401e073eb20a4f32dd
https://doi.org/10.1200/jco.2021.39.15_suppl.e21569
https://doi.org/10.1200/jco.2021.39.15_suppl.e21569